Key Highlights

Risk & Performance

Based on historical performance

Moderate Risk

Score: 55/100

Failure Rate

25.0%

1 terminated/withdrawn out of 4 trials

Success Rate

66.7%

-19.8% vs industry average

Late-Stage Pipeline

50%

2 trials in Phase 3/4

Results Transparency

0 of 2 completed trials have results

Key Signals

1 recruiting

N/A

2(50.0%)

Phase 3

2(50.0%)

4Total

N/A(2)

Phase 3(2)

Loading network data...

Showing 4 of 4 trials

Marker - Adjusted Therapy Comparing Adjuvant Elacestrant With Standard Endocrine Treatment in Genomically and/or Clinically High-risk ER+/HER2- eBC

Role: collaborator

Prevention of Stroke and Dementia in Primary Care

Role: collaborator

Effects of Nebivolol on Subclinical Left Ventricular dySfunction: A Comparative Study Against Metoprolol

Role: lead

Glycemic Rises After Waking Up In Response To An Alarm Clock In Type 1-Diabetic Patients Analysed With Continuous Glucose Monitoring (GlucoDay®)

Role: collaborator

All 4 trials loaded